Buchang Pharmaceutical Co., Ltd.: Inheriting and carrying forward Chinese medicine culture and digging deep into the essence of Chinese culture.

The origin of traditional Chinese medicine is due to the need of human survival. Since the emergence of human beings, there have been diseases and pains, and healing wounds requires medical knowledge and skills, so there has been Chinese medicine. With the people of China, there will be Chinese medicine, which originated from primitive society, accumulated and created by working people in their long-term production and life practice, and is the product of practice. After the pre-Qin, Qin and Han dynasties, Chinese medicine has accumulated rich experience and knowledge in basic theories such as human body structure, physiology, pathology, diagnosis, syndrome differentiation, treatment principles and methods, and clinical application of Chinese medicine.

Guided by the overall concept, Chinese medicine pursues the harmonious life between man and nature, and advocates the ideas of health care, individualized diagnosis and treatment, and dialectical treatment, which conforms to the concept and direction of modern medical development. Nowadays, it has become a new lifestyle and trend to see Chinese medicine practitioners and eat Chinese medicine overseas. According to Zhang Boli, former president of Chinese Academy of Traditional Chinese Medicine, 70% of Chinese medicine practitioners abroad are foreign Chinese medicine practitioners; 70% of the patients served by Chinese medicine are foreigners. Chinese medicine is gradually entering the lives of ordinary people in various countries. Consumers can also attend health talks in overseas shops of the Museum of Traditional Chinese Medicine, and learn China traditional health preserving methods such as Tai Ji Chuan, Baduanjin and Wuqinxi. In the past thousands of years, the Chinese nation has relied on Chinese medicine to cure diseases and save lives. Especially after fighting COVID-19 epidemic, SARS and other major infectious diseases, we have a deeper understanding of the role of traditional Chinese medicine. To develop traditional Chinese medicine, we should pay attention to explaining the principles of traditional Chinese medicine with modern science and take the road of combining traditional Chinese and western medicine.

Buchang Pharmaceutical, one of the leading Chinese medicine enterprises, recently announced that Xuanfei Baidu Granule was included in the national medical insurance catalogue for the first time after negotiation. In addition, Buchang Pharmaceutical also announced the announcement of newly obtained invention patent certificate. According to the announcement, Buchang Pharmaceutical's two patents, namely "an anti-coronavirus Chinese medicine granule and its preparation method and application" and "an anti-coronavirus Chinese medicine composition and its application in treating inflammation", have recently obtained the invention patent certificate issued by China National Intellectual Property Administration.

The Xuanfei Baidu Granule that Buchang Pharmaceutical included in the medical insurance this time is a newly approved drug listed this year, which is its exclusive variety. What is more noteworthy is that the anti-epidemic effect of Xuanfei Baidu Granule is remarkable, and its future market is full of imagination.

"Xuanfeibaidu Granule" is a convenient granule based on the classic ancient prescription Xuanfeibaidu Formula and modern Chinese medicine preparation technology. Its indications are: it is mainly used to treat diseases caused by damp-toxic stagnation of lung, with symptoms of fever, cough, throat discomfort, shortness of breath, red and dark tongue, yellow and greasy fur or dry, slippery or stringy pulse.

Buchang Pharmaceutical's prescription for dispersing lung and detoxifying is an effective prescription summarized by Academician Zhang Boli's team in the clinical treatment of COVID-19 patients in Wuhan frontline. It is also the first variety to be evaluated and approved according to the Requirements for Registration and Classification of Traditional Chinese Medicine (No.68 in 2020) and "3.2 Other Traditional Chinese Medicine Compound Preparations from Ancient Classic Prescriptions" after the reform of registration and classification of traditional Chinese medicine. Academician Zhang Boli once said that Xuanfei Baidu Granule is an ancient prescription of traditional Chinese medicine and the crystallization of modern science and technology. The treatment of COVID-19 has scientific basis, which is the embodiment of the great progress of "Chinese medicine plus science and technology".

In fact, from the application effect of traditional Chinese medicine, compared with chemical drugs, multi-target therapy is the unique advantage of traditional Chinese medicine in treating complex diseases. Traditional Chinese Medicine (TCM) has played a unique role in the fight against COVID-19 epidemic with its remarkable advantages of multi-target treatment. According to statistics, in the process of treating COVID-19, there are 60,000 confirmed cases treated by traditional Chinese medicine in China, and more than 80% of the patients have received traditional Chinese medicine treatment.

Recently, the State Council issued "Several Policies and Measures on Accelerating the Development of Chinese Medicine Characteristics", pointing out that there are still some problems in Chinese medicine, such as insufficient quality supply, insufficient total talents, imperfect innovation system and outstanding development characteristics. It is suggested that we should follow the development law of Chinese medicine, sum up the experience and practice of Chinese medicine in preventing and treating COVID-19, solve the existing problems, give play to the characteristics and comparative advantages of Chinese medicine, and promote the complementary and coordinated development of Chinese and Western medicine.

Mr. Zhao Tao, Chairman of Buchang Pharmaceutical, said at the Boao China Entrepreneur Forum held in Boao, Hainan Province in February, 200212002: Buchang Pharmaceutical has built a clear development strategy, that is, taking patented Chinese patent medicines as the core, devoting itself to the modernization of Chinese medicine, giving full play to the important role of Chinese medicine in the cardiovascular and cerebrovascular fields, and forming a three-dimensional development based on the cardiovascular and cerebrovascular market, covering the traditional advantages of Chinese patent medicines and focusing on serious diseases. Since its establishment, Buchang Pharmaceutical has been committed to vigorously revitalizing national brands with the world pattern and vision. In the future development, Buchang Pharmaceutical will actively practice the concept of * * * and become a responsible, responsible and respected China enterprise!

Judging from the core R&D team of the company, the "medical expert attribute" of the founders and executives has played an important role in the research and development of the company's proprietary Chinese medicines. Mr. Zhao Tao, Chairman of Buchang Pharmaceutical Co., Ltd., has more than 30 years of working experience in the pharmaceutical industry and rich experience in medical theory and practice. He is the main inventor of many products and patented technologies of the company. Zhao Tao believes that entrepreneurs in the new era should not only do their jobs well in pharmaceutical enterprises, but also undertake their mission responsibilities, try their best to help more people and make contributions to society.

Mr. Zhao Buchang, the founder of Buchang Pharmaceutical Co., Ltd., as an expert in the field of cardiovascular and cerebrovascular diseases, first put forward the slogan of "treating both heart and brain, and curative effect is the last word", which has a very high influence in the fields of heart and brain therapy and Chinese pharmacy. It is understood that as early as 1992, Mr. Zhao Buchang won the "special government allowance" of the State Council, and his "Bubu Naoxintong" won the Science and Technology Achievement Award of the Ministry of Health twice. In 2004, he was awarded the honorary title of "Excellent Socialism with Chinese characteristics Career Builder", and in the same year, he was awarded the qualification of lifelong academician of the Department of Enterprise Management by the Chinese Academy of Management Sciences.

In fiscal year 2022, the market paid special attention to Buchang Pharmaceutical's new anti-epidemic product "Xuanfei Baidu Granule". As a benchmark product, the sales volume of Lianhua Qingwen series products of Yiling Pharmaceutical has maintained a high growth since the epidemic in 2020. In 2020 alone, this series of products created sales of 4.26 billion yuan, up 150% year-on-year, accounting for half of all sales of Yiling Pharmaceutical. Yiling Pharmaceutical also achieved a year-on-year increase in revenue of 50.76% and a year-on-year increase in net profit of 65,438. With this good example, Buchang Pharmaceutical's "Xuanfei Baidu Granule" undoubtedly makes investors full of expectations. In the long run, this product will promote the steady improvement of Buchang Pharmaceutical's performance.